60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments.

Publication

60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments.

Journal Paper/Review - Mar 6, 2020

Kaufmann Marco, Puhan Milo Alan, Salmen Anke, Kamm Christian Philipp, Manjaly Zina-Mary, Calabrese Pasquale, Schippling Sven, Müller Stefanie, Kuhle Jens, Pot Caroline, Gobbi Claudio, Steinemann Nina, von Wyl Viktor, Swiss Multiple Sclerosis Registry (SMSR)

Citation

Kaufmann M, Puhan M, Salmen A, Kamm C, Manjaly Z, Calabrese P, Schippling S, Müller S, Kuhle J, Pot C, Gobbi C, Steinemann N, von Wyl V, Swiss Multiple Sclerosis Registry (SMSR). 60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments. Front Neurol 2020; 11:156.

Type

Journal Paper/Review (English)

Journal

Front Neurol 2020; 11

Publication Date

Mar 6, 2020

Issn Print

1664-2295

Pages

156

Brief description/objective

Multiple sclerosis (MS) is the most common chronic, non-traumatic, neurologic disease in young adults. While approximate values of the disease burden of MS are known, individual drivers are unknown. To estimate the age-, sex-, and disease severity-specific contributions to the disease burden of MS. We estimated the disease burden of MS using disability-adjusted life years (DALYs) following the Global Burden of Disease study (GBD) methodology. The data sources consisted of the Swiss MS Registry, a recent prevalence estimation, and the Swiss mortality registry. The disease burden of MS in Switzerland in 2016 was 6,938 DALYs (95%-interval: 6,018-7,955), which corresponds to 97 DALYs per 100,000 adult inhabitants. Morbidity contributed 59% of the disease burden. While persons in an asymptomatic (EDSS-proxy 0) and mild (EDSS-proxy >0-3.5) disease stage represent 68.4% of the population, they make up 39.8% of the MS-specific morbidity. The remaining 60.2% of the MS-specific morbidity stems from the 31.6% of persons in a moderate (EDSS-proxy 4-6.5) or severe (EDSS-proxy ≥7) disease stage. Morbidity has a larger influence on the disease burden of MS than mortality and is shared in a ratio of 2:3 between persons in an asymptomatic/mild and moderate/severe disease stage in Switzerland. Interventions to reduce severity worsening in combination with tailored, symptomatic treatments are important future paths to lower the disease burden of MS.